18:56 , Jul 13, 2018 |  BC Week In Review  |  Financial News

Idorsia raises $511.9M in dual offerings

Idorsia Ltd. (SIX:IDIA) raised on July 11 CHF505.2 million ($511.9 million) in a pair of private placements underwritten by Credit Suisse, Goldman Sachs and Octavian. Idorsia raised CHF305.2 million ($309.2 million) through the sale of...
18:36 , Jul 12, 2018 |  BC Extra  |  Financial News

Idorsia raises $511.9M in dual offerings

Idorsia Ltd. (SIX:IDIA) raised CHF505.2 million ($511.9 million) in a pair of private placements underwritten by Credit Suisse, Goldman Sachs and Octavian. Idorsia raised CHF305.2 million ($309.2 million) through the sale of 11.9 million shares...
20:41 , Sep 8, 2017 |  BC Week In Review  |  Clinical News

FDA approves Tracleer for pediatric PAH

FDA approved a 32 mg tablet of Tracleer bosentan to treat pulmonary arterial hypertension in children ages 3 and older. Johnson & Johnson (NYSE:JNJ) gained Tracleer in its June acquisition of Actelion Ltd. Actelion said...
23:20 , Sep 6, 2017 |  BC Extra  |  Company News

FDA approves Tracleer for pediatric PAH

FDA approved a 32 mg tablet of Tracleer bosentan to treat pulmonary arterial hypertension in children ages three and older. Johnson & Johnson (NYSE:JNJ) gained Tracleer in its June acquisition of Actelion Ltd. Actelion said...
19:33 , Jun 16, 2017 |  BC Extra  |  Financial News

Actelion spinout Idorsia rises in first trading day

Idorsia Ltd. (SIX:IDIA) gained CHF3.65 (37%) to CHF13.65 in its first day of trading on Friday. The closing price valued the company at CHF1.5 billion ($1.5 billion). Idorsia was spun out of Actelion Ltd. (SIX:ATLN),...
23:39 , Jun 9, 2017 |  BC Extra  |  Financial News

Actelion spinout Idorsia to list next week

On June 16, shares of Idorsia Ltd. (Allschwil, Switzerland) are to begin trading on the SIX Swiss Exchange. Idorsia will house the drug discovery and early clinical pipeline businesses of Actelion Ltd. (SIX:ATLN), which Johnson...
03:07 , Feb 4, 2017 |  BioCentury  |  Strategy

Actelion, take two

After surviving takeover attempts, an investor mutiny and a make-or-break gamble on Opsumit macitentan, Actelion Ltd. co-founder and CEO Jean-Paul Clozel finally took a deal management couldn’t refuse. Johnson & Johnson ’s proposed $30 billion...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

Letairis regulatory update

The European Commission approved an expanded label for Volibris ambrisentan from GlaxoSmithKline to treat pulmonary arterial hypertension (PAH) classified as World Health Organization (WHO) Functional Class II and III to include its use in combination...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

Letairis regulatory update

EMA’s CHMP recommended approval of a label extension for Volibris ambrisentan from GlaxoSmithKline to include use in combination treatment for pulmonary arterial hypertension (PAH). GSK, which has ex-U.S. commercialization rights to the product from Gilead,...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Clinical News

Letairis: Additional Phase IIIb/IV data

Gilead previously reported that the combination arm met the primary endpoint in the trial (see BioCentury, Nov. 10, 2014). An sNDA for the combination treatment to treat PAH is under FDA review with an Oct....